Literature DB >> 8577720

Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.

J S Kovach1, A Hartmann, H Blaszyk, J Cunningham, D Schaid, S S Sommer.   

Abstract

Human cancer cells with a mutated p53 tumor-suppressor gene have a selective growth advantage and may exhibit resistance to ionizing radiation and certain chemotherapeutic agents. To examine the prognostic value of mutations in the p53 gene, a cohort of 90 Midwestern Caucasian breast cancer patients were analyzed with methodology that detects virtually 100% of all mutations. The presence of a p53 gene mutation was by far the single most predictive indicator for recurrence and death (relative risks of 4.7 and 23.2, respectively). Direct detection of p53 mutations had substantially greater prognostic value than immunohistochemical detection of p53 overexpression. Analysis of p53 gene mutations may permit identification of a subset of breast cancer patients who, despite lack of conventional indicators of poor prognosis, are at high risk of early recurrence and death.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8577720      PMCID: PMC40036          DOI: 10.1073/pnas.93.3.1093

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Dideoxy fingerprinting (ddE): a rapid and efficient screen for the presence of mutations.

Authors:  G Sarkar; H S Yoon; S S Sommer
Journal:  Genomics       Date:  1992-06       Impact factor: 5.736

2.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

3.  Rapid and efficient screening for p53 gene mutations by dideoxy fingerprinting.

Authors:  H Blaszyk; A Hartmann; J J Schroeder; R M McGovern; S S Sommer; J S Kovach
Journal:  Biotechniques       Date:  1995-02       Impact factor: 1.993

4.  Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers.

Authors:  N Jego; G Thomas; R Hamelin
Journal:  Oncogene       Date:  1993-01       Impact factor: 9.867

5.  Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas.

Authors:  J S Kovach; R M McGovern; J D Cassady; S K Swanson; L E Wold; B Vogelstein; S S Sommer
Journal:  J Natl Cancer Inst       Date:  1991-07-17       Impact factor: 13.506

6.  p53 mutations occur in aggressive breast cancer.

Authors:  R Mazars; L Spinardi; M BenCheikh; J Simony-Lafontaine; P Jeanteur; C Theillet
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

7.  Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.

Authors:  S Thorlacius; A L Börresen; J E Eyfjörd
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

Review 8.  A comparison of the biological activities of wild-type and mutant p53.

Authors:  G P Zambetti; A J Levine
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

9.  Parameters affecting the sensitivities of dideoxy fingerprinting and SSCP.

Authors:  Q Liu; S S Sommer
Journal:  PCR Methods Appl       Date:  1994-10

10.  p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade.

Authors:  H Tsuda; K Iwaya; T Fukutomi; S Hirohashi
Journal:  Jpn J Cancer Res       Date:  1993-04
View more
  24 in total

Review 1.  Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.

Authors:  R J Michalides
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

2.  Prognostic significance of regulators of cell cycle and apoptosis, p16(INK4a), p53, and bcl-2 in primary mucosal melanomas of the head and neck.

Authors:  Manju L Prasad; Snehal G Patel; Jatin P Shah; Stacy Hoshaw-Woodard; Klaus J Busam
Journal:  Head Neck Pathol       Date:  2011-12-13

3.  Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival.

Authors:  A N Jain; K Chin; A L Børresen-Dale; B K Erikstein; P Eynstein Lonning; R Kaaresen; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Detection of all single-base mismatches in solution by chemiluminescence.

Authors:  N C Nelson; P W Hammond; E Matsuda; A A Goud; M M Becker
Journal:  Nucleic Acids Res       Date:  1996-12-15       Impact factor: 16.971

5.  Rapid and Sensitive Detection of p53 Based on DNA-Protein Binding Interactions Using Silver Nanoparticle Films and Microwave Heating.

Authors:  Muzaffer Mohammed; Kadir Aslan
Journal:  Nano Biomed Eng       Date:  2014-11-10

6.  Analysis of p53 mutation and cyclin D1 expression in breast tumors.

Authors:  J Tanyi; K Tory; A Bánkfalvi; W Shröder; W Rath; L Füzesi
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

7.  The mechanism of the adsorption of dsDNA on citrate-stabilized gold nanoparticles and a colorimetric and visual method for detecting the V600E point mutation of the BRAF gene.

Authors:  Zhen Liu; Menik Hettihewa; Yang Shu; Chunqiong Zhou; Qian Wan; Lihong Liu
Journal:  Mikrochim Acta       Date:  2018-03-27       Impact factor: 5.833

8.  p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

Authors:  T Megha; F Ferrari; A Benvenuto; C Bellan; A V Lalinga; S Lazzi; S Bartolommei; G Cevenini; L Leoncini; P Tosi
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

9.  Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.

Authors:  C I Huang; N Kohno; E Ogawa; M Adachi; T Taki; M Miyake
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

10.  Is Nothingham Prognostic Index correlated with apoptosis and p53 expression in infiltrating ductal carcinoma of the breast?

Authors:  Esin Cengiz-Boduroglu; Cigdem Irkkan; Gülay Bilir
Journal:  Pathol Oncol Res       Date:  2003-07-14       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.